Quelles thérapeutiques proposer dans la maladie de Parkinson du sujet âgé ?
Tóm tắt
Từ khóa
Tài liệu tham khảo
Muangpaisan W, Mathews A, Hori H, Seidel D (2011) A systematic review of the worldwide prevalence and incidence of Parkinson’s disease. J Med Assoc Thai 94:749–755
Dowding CH, Shenton CL, Salek SS (2006) A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging 23:693–721
Chen JJ (2010) Parkinson’s disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag Care 16 Suppl Implications:S87–S93
Kaltenboeck A, Johnson SJ, Davis MR, et al (2011) Direct costs and survival of medicare beneficiaries with early and advanced parkinson’s disease. Parkinsonism Relat Disord [Epub ahead of print]
Gage H, Hendricks A, Zhang S, Kazis L (2003) The relative health related quality of life of veterans with Parkinson’s disease. J Neurol Neurosurg Psychiatry 74:163–169
Soh SE, Morris ME, McGinley JL (2011) Determinants of healthrelated quality of life in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 17:1–9
Conférence de consensus (2000) Maladie de Parkinson: diagnostic et traitement. Rev Neurol (Paris) 156Suppl 2 Pt 2:281–294
Goetz CG, Poewe W, Rascol O, Sampaio C (2005) Evidencebased medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disord 20:523–539
Fox SH, Katzenschlager R, Lim SY, et al (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 26Suppl 3:S2–S41
Seppi K, Weintraub D, Coelho M, et al (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26 Suppl 3:S42–S80
Jego M, Viallet F (2009) Maladie de Parkinson du sujet âgé: prise en carge thérapeutique: médicaments à prescrire, médicaments à éviter. Rev Geriatr 34:8–11
Geny C (2009) Spécificités gériatriques de la maladie de Parkinson. Rev Geriatr 34:4–7
Petit H, Vermersch P, Pasquier F (1992) Some clinical aspects of late onset parkinsonism. Clin Neurol Neurosurg 94Suppl: S137–S138
Diederich NJ, Moore CG, Leurgans SE, et al (2003) Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 60:529–533
Hobson P, Meara J (2004) Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 19:1043–1049
Friedman A (1994) Old-onset Parkinson’s disease compared with young-onset disease: clinical differences and similarities. Acta Neurol Scand 89:258–261
Gibb WR, Lees AJ (1988) A comparison of clinical and pathological features of young- and old-onset Parkinson’s disease. Neurology 38:1402–1406
Bainbridge JL, Ruscin JM (2009) Challenges of treatment adherence in older patients with Parkinson’s disease. Drugs Aging 26:145–155
Grosset D, Antonini A, Canesi M, et al (2009) Adherence to antiparkinson medication in a multicenter European study. Mov Disord 24:826–832
Lauretani F, Maggio M, Silvestrini C, et al (2012) Parkinson’s disease (PD) in the elderly: an example of geriatric syndrome (GS)? Arch Gerontol Geriatr 54:242–246
Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson’s disease: a populationbased, prospective study. J Am Geriatr Soc 48:938–942
Leopold NA, Polansky M, Hurka MR (2004) Drug adherence in Parkinson’s disease. Mov Disord 19:513–517
Peterson AM, Takiya L, Finley R (2003) Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 60:657–665
Schlenk EA, Bernardo LM, Organist LA, et al (2008) Optimizing Medication Adherence in Older Patients: A Systematic Review. J Clin Outcomes Manag 15:595–606
Marciniak CM, Choo CM, Toledo SD, et al (2011) Do comorbidities and cognition impact functional change and discharge needs in Parkinson disease? Am J Phys Med Rehabil 90:272–280
Goy ER, Carter JH, Ganzini L (2008) Needs and experiences of caregivers for family members dying with Parkinson disease. J Palliat Care 24:69–75
Lanoix M (2009) Palliative care and Parkinson’s disease: managing the chronic-palliative interface. Chronic Illn 5:46–55
Lokk J (2011) Parkinson’s disease permanent care unit: managing the chronic-palliative interface. J Multidiscip Healthc 4:33–38
Rascol O, Brooks DJ, Melamed E, et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947–954
Pellicano C, Benincasa D, Giovannelli M, et al (2009) Entacapone in elderly Parkinsonian patients experiencing levodoparelated wearing-off: a pilot study. Neurol Res 31:74–76
Goetz CG, Schwid SR, Eberly SW, et al (2006) Safety of rasagiline in elderly patients with Parkinson disease. Neurology 66:1427–1429
Tolosa E, Stern MB (2011) Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease. Eur J Neurol 19:258–264
Chen JJ, Fernandez HH (2007) Community and long-term care management of Parkinson’s disease in the elderly: focus on monoamine oxidase type B inhibitors. Drugs Aging 24:663–680
Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al (2008) Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov Disord 23:1130–1136
Devos D (2009) Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord 24:993–1000
Shulman LM, Minagar A, Rabinstein A, Weiner WJ (2000) The use of dopamine agonists in very elderly patients with Parkinson’s disease. Mov Disord 15:664–668
Derost PP, Ouchchane L, Morand D, et al (2007) Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology 68:1345–1355
Vesper J, Haak S, Ostertag C, Nikkhah G (2007) Subthalamic nucleus deep brain stimulation in elderly patients—analysis of outcome and complications. BMC Neurol 7:7
Rouaud T, Dondaine T, Drapier S, et al (2010) Pallidal stimulation in advanced Parkinson’s patients with contraindications for subthalamic stimulation. Mov Disord 25:1839–1846
Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al (2010) The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25:704–709
Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR (2011) The impact of non-motor symptoms on healthrelated quality of life of patients with Parkinson’s disease. Mov Disord 26:399–406
Margis R, Donis KC, Schonwald SV, Rieder CR (2010) WHOQOL-OLD assessment of quality of life in elderly patients with Parkinson’s disease: influence of sleep and depressive symptoms. Rev Bras Psiquiatr 32:125–131
Reichmann H, Schneider C, Lohle M (2009) Non-motor features of Parkinson’s disease: depression and dementia. Parkinsonism Relat Disord 15 Suppl 3:S87–S92
Winter Y, von Campenhausen S, Arend M, et al (2011) Healthrelated quality of life and its determinants in Parkinson’s disease: results of an Italian cohort study. Parkinsonism Relat Disord 17:265–269
Truong DD, Bhidayasiri R, Wolters E (2008) Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 266:216–228
Zesiewicz TA, Sullivan KL, Arnulf I, et al (2010) Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 74:924–931